Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Encysive To Cut U.S. Work Force By 70 Percent To Curb Cash Flow

This article was originally published in The Pink Sheet Daily

Executive Summary

Company also appoints George Cole to CEO, replacing Bruce Given, following on the heels of an FDA “approvable” letter for Thelin.

You may also be interested in...



Encysive To Enter Dispute Resolution With FDA Over Third Thelin “Approvable” Letter

Company asserts that FDA’s data analysis of STRIDE-2 trial for Thelin does not follow special protocol assessment agreement.

Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial

Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.

Bayer's Finerenone Stacks Up More CV Benefit Data Ahead Of Potential Approval

The FIGARO-DKD cardiovascular outcomes trial showed finerenone reduced composite risk of CV death or non-fatal events in CKD patients with Type 2 diabetes, including earlier-stage patients.

Topics

UsernamePublicRestriction

Register

PS066235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel